Oncology companies develop therapies, diagnostics and technologies that support the detection, monitoring and treatment of cancer. The sector is one of the largest and most active areas of biotechnology and pharmaceutical innovation.
This category includes companies working on:
Browse 291 UK oncology companies below.
CRISPR-engineered tumour-infiltrating lymphocyte therapy
Intima Bioscience is a clinical-stage biotechnology company developing CRISPR gene-edited tumour-infiltrating lymphocyte therapies for solid tumours. Its platform targets CISH, an intracellular immune checkpoint that suppresses T cell activity against tumours; CRISPR knockout of CISH in patient-derived TILs enhances…
Fragment-based drug discovery with a glioblastoma focus
IOTA Pharmaceuticals is a Cambridge drug discovery company specialising in fragment-based design, molecular screening and computational approaches to early-stage therapeutics. Its research combines transcriptomics, phenotypic assays and natural product screening to investigate candidate treatments. A major focus is…
Bispecific antibody-drug conjugates for cancer-selective precision therapy
BiVictriX Therapeutics is a biopharmaceutical company developing bispecific antibody-drug conjugates for targeted cancer treatment. Its Bi-Cygni platform recognises combinations of two tumour-associated antigens to improve cancer-cell selectivity and limit effects on healthy tissues. Its lead solid-tumour candidate,…
ML platform designing optimised CAR-T and BiTE therapies
Coding Bio is a biotechnology company using machine learning and high-throughput screening to design chimeric antigen receptor and bispecific T cell engager therapies. The company's platform screens millions of modular protein candidates in living cells to identify designs that best induce immune responses, generating…
AI-driven tRNA synthetase platform for novel small molecule therapeutics
Oxford Drug Design is an Oxford biotech developing small molecule therapeutics using an integrated platform combining aminoacyl-tRNA synthetase biology with proprietary generative AI and machine learning. The platform provides structural biology knowledge, crystallographic data, and novel chemotypes targeting tRNA…
Pharma-university venture funding early-stage translational research
Apollo Therapeutics is a biopharma company advancing therapeutic programmes derived from research at partner universities including Cambridge, Imperial College London, UCL, King's College London, and the Institute of Cancer Research. Originally a joint venture between three universities and AstraZeneca, GSK, and…
Multispecific immune cell engagers targeting gamma delta T cells
Cytospire Therapeutics is developing multispecific engager antibodies designed to enhance and direct the activity of gamma delta T cells for the treatment of cancer and autoimmune disease. The company emerged from stealth in 2024, backed by Abingworth, 4BIO Capital and LifeArc Ventures. Its platform targets both…
Targeted small-molecule drugs for brain and metastatic cancers
Sentinel Oncology is a biotechnology company developing targeted small-molecule drugs for difficult-to-treat cancers. Its medicinal chemistry programmes investigate DNA damage responses and cell division. Some candidates are designed to cross the blood-brain barrier, targeting primary brain tumours and cancers that…
Long-acting GnRH antagonist for prostate cancer and urinary retention
Antev is a clinical-stage biopharmaceutical company developing a long-acting gonadotropin-releasing hormone (GnRH) antagonist that suppresses testosterone production. Its lead peptide therapy is being developed for men with advanced prostate cancer, including those at high cardiovascular risk, and for men experiencing…
Bayesian oncology models for treatment-response prediction and research
Concr is a London biotechnology software company using astrophysics-derived Bayesian AI to model individual cancer biology and predict treatment responses. Its FarrSight platform combines genomic, molecular and clinical datasets in digital twins, supporting research into patient stratification and oncology drug…
TCR-based bispecific therapeutics for cancer and autoimmune disease
T-Therapeutics is a biotechnology company developing T cell receptor-based therapeutics for cancer and autoimmune disease. Using a humanised TCR mouse platform to generate high-affinity, antigen-specific human T cell receptors, the company engineers bispecific molecules that redirect a patient's own T cells to…
Specialty biopharma with UK neurotoxin manufacturing hub
Ipsen is a French specialty biopharmaceutical company with one of three global hubs based in the UK. Its Wrexham site serves as the company's global neuroscience centre of excellence, responsible for research, development and manufacture of neurotoxin products including botulinum toxin. The London site houses…
Quantum simulation and AI platform for enzyme-targeted drug discovery
Kuano is a computational drug discovery company combining quantum simulation with artificial intelligence to design inhibitors against enzyme targets. The platform models transition states during enzyme reactions, quantum mechanical events inaccessible to classical structure-based methods generating a Quantum…
Programmable iPSC cell therapies for cancer and autoimmunity
Xap Therapeutics is a Cambridge-based biotechnology company developing a synthetic biology platform for next-generation cell therapeutics. The company applies CRISPR technology to engineer induced pluripotent stem cells (iPSCs) into a universal "chassis" cell that can be functionalised with engineered receptors and…
Cancer Research UK's translational and commercialisation arm
Cancer Research Horizons is the translational subsidiary of Cancer Research UK, operating at the interface between academic research and industry. The organisation combines in-house drug discovery expertise across six UK sites with technology transfer, licensing, and early-stage venture investment activities. It…
Full-service CRO specialising in oncology and rare diseases
Simbec-Orion is a full-service CRO providing Phase I to Phase IV clinical trial services, with specialist expertise in oncology, rare and orphan diseases, and clinical pharmacology. Its Merthyr Tydfil campus houses a 58-bed MHRA-accredited Phase I unit, Seirian Laboratories for central pathology and bioanalysis, IMP…
Shark-derived single-domain antibody biologics for cancer and inflammation
Elasmogen is a biotechnology company developing next-generation therapeutic biologics based on its proprietary soloMER platform, single-domain antibody-like proteins derived from the shark immune system. soloMERs offer advantages over conventional antibodies in size, stability, and tissue penetration. The pipeline…
Implantable localised chemotherapy delivery for hard-to-treat solid tumours
CRISM Therapeutics is a clinical-stage drug delivery company developing an implantable biodegradable technology that delivers chemotherapy directly into tumours or surgical margins, reducing the systemic side effects of conventional treatment. Developed with the University of Birmingham, the company's lead programme…
Biparatopic PD-1/VEGFR2 antibody for solid tumour oncology
Ottimo Pharma is a clinical-stage biotechnology company developing biparatopic antibody therapeutics for solid tumour cancers. Its lead programme, Jankistomig, is a first-in-class single-agent IgG antibody that simultaneously targets PD-1 for immune checkpoint inhibition and VEGFR2 to suppress tumour angiogenesis. The…
Specialist molecular pathology, histopathology and spatial biology CRO
Propath (UK) is a contract research organisation providing GLP and GCP-compliant molecular pathology, histopathology, and spatial biology services to the global biopharmaceutical industry. Operating from a dedicated 12,000 square foot facility in Hereford, the company delivers spatial transcriptomics, highly…